NDAINTRAVENOUSSOLUTION
Approved
Feb 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
ANJESO (meloxicam) by Ascentage Pharma is analgesic, anti-inflammatory, and antipyretic properties. Approved for osteoarthritis, rheumatoid arthritis, ankylosing spondylitis. First approved in 2020.
Drug data last refreshed 20h ago
Mechanism of Action
analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of meloxicam, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). Meloxicam is a potent inhibitor of prostaglandin synthesis in vitro. Meloxicam…
Indications (3)
Worked on ANJESO at Ascentage Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.